|
市場調査レポート
商品コード
1672684
全身性強皮症治療市場：薬剤クラス別、タイプ別、投与経路別、流通チャネル別、地域別Systemic Scleroderma Treatment Market, By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
カスタマイズ可能
|
|||||||
| 全身性強皮症治療市場：薬剤クラス別、タイプ別、投与経路別、流通チャネル別、地域別 |
|
出版日: 2025年02月07日
発行: Coherent Market Insights
ページ情報: 英文 164 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
全身性強皮症治療の世界市場は、2025年には18億米ドルと推定され、2032年には25億5,000万米ドルに達すると予測され、2025年から2032年にかけてCAGR5.1％で成長する見込みです。
| レポート範囲 | レポート詳細 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年の市場規模 | 18億米ドル |
| 実績データ | 2020年から2024年まで | 予測期間 | 2025年から2032年 |
| 予測期間：2025年～2032年 CAGR： | 5.10% | 2032年の価値予測 | 25億5,000万米ドル |
全身性強皮症は、皮膚や結合組織の硬化や引き締めを引き起こす慢性の自己免疫性結合組織疾患です。身体の細胞や組織におけるコラーゲンの過剰産生が特徴で、線維化や瘢痕化を引き起こします。現在、全身性強皮症の治療法は確立されておらず、症状を管理し、病気の進行を遅らせるための治療法は限られています。全身性強皮症治療市場は、この疾患の治療に使用される薬剤、治療薬、医療機器、その他の製品で構成されています。有病率の上昇と限られた治療選択肢により、この市場は今後数年で大きく成長する見込みです。
市場力学：
世界の全身性強皮症治療市場は、世界の全身性強皮症の罹患率と有病率の増加によって牽引されています。強皮症財団によると、米国では約30万人、世界では数百万人が強皮症を患っています。しかしながら、疾患の病因に関する理解が限られていること、治療選択肢が乏しいこと、全身型に対して承認された薬剤がないことが、市場成長の課題となっています。しかし、現在進行中の新薬や治療法の研究は、治療の展望を広げる可能性を秘めています。さらに、主要市場におけるヘルスケア支出の増加は、2030年までの市場拡大を促進すると思われます。
本調査の主な特徴
本レポートでは、世界の全身性強皮症治療市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模およびCAGRを掲載しています。
また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
世界の全身性強皮症治療市場における主要企業を、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。
本調査の対象となる主要企業には、GSK plc、Certa Therapeutics、Aisa Pharma, Inc.、Corbus Pharmaceuticals、AbbVie, Inc.、Biogen、Novartis AG、AstraZeneca、Celgen Corporation、ONO PHARMACEUTICAL CO., LTD.、Teva Pharmaceutical Industries Ltd.、Boehringer Ingelheim International GmbH.、MediciNova, Inc.などがあります。
本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関して、十分な情報に基づいた意思決定を行うことができます。
世界の全身性強皮症治療市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者を対象としています。
利害関係者は、世界の全身性強皮症治療市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。
目次
第1章 調査の目的と前提条件
- 調査目的
- 前提条件
- 略語
第2章 市場の展望
- レポートの説明
- 市場の定義と範囲
- エグゼクティブサマリー
第3章 市場力学、規制、動向分析
- 市場力学
- 影響分析
- 主なハイライト
- 規制シナリオ
- 製品の発売/承認
- PEST分析
- PORTERの分析
- 合併と買収のシナリオ
- 疫学
第4章 全身性強皮症治療市場、薬剤クラス別、2020年～2032年、（10億米ドル）
- 免疫抑制剤
- ホスホジエステラーゼ5阻害剤-PHA
- エンドセリン受容体拮抗薬
- カルシウムチャネル遮断薬
- プロスタサイクリン類似体
- その他
第5章 全身性強皮症治療市場、タイプ別、2020年～2032年、（10億米ドル）
- 限局型全身性強皮症
- びまん性全身性強皮症
- 皮膚硬化をみない強皮症
第6章 全身性強皮症治療市場、投与経路別、2020年～2032年、（10億米ドル）
- 経口
- 非経口
- その他
第7章 全身性強皮症治療市場、流通チャネル別、2020年～2032年、（10億米ドル）
- 病院薬局
- オンライン薬局
- 小売薬局
第8章 全身性強皮症治療の世界市場、地域別、2020年-2032年、価値（10億米ドル）
- 北米
- ラテンアメリカ
- 欧州
- アジア太平洋
- 中東
- アフリカ
第9章 競合情勢
- GSK plc
- Certa Therapeutics
- Aisa Pharma, Inc.
- Corbus Pharmaceuticals
- AbbVie, Inc.
- Biogen
- Novartis AG
- AstraZeneca
- Celgen Corporation
- ONO PHARMACEUTICAL CO., LTD.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH.
- MediciNova, Inc.
第10章 アナリストの推奨事項
第11章 参考文献と調査手法
- 参考文献
- 調査手法
- 出版社について
Global Systemic Scleroderma Treatment Market is estimated to be valued at USD 1.80 Bn in 2025 and is expected to reach USD 2.55 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 1.80 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.10% | 2032 Value Projection: | USD 2.55 Bn |
Systemic scleroderma is a chronic autoimmune connective tissue disorder that causes hardening and tightening of the skin and connective tissues. It is characterized by the overproduction of collagen in the cells and tissues of the body leading to fibrosis or scarring. Currently, there is no cure for systemic scleroderma and the treatment options are limited to manage its symptoms and slow disease progression. The systemic scleroderma treatment market comprises drugs, therapies, medical devices and other products being used to treat this condition. With rising prevalence and limited treatment options, this market is poised to grow significantly in the coming years.
Market Dynamics:
The global systemic scleroderma treatment market is driven by the increasing incidence and prevalence of systemic scleroderma worldwide. According to Scleroderma Foundation, around 300,000 people in the U.S. and millions worldwide suffer from scleroderma. However, limited understanding of disease etiology, scarce treatment options, and lack of approved drugs for systemic forms pose challenges to market growth. Nonetheless, ongoing research on novel drugs and therapies holds promise to widen the treatment landscape. Furthermore, rising healthcare expenditures in major markets will facilitate market expansion through 2030.
Key Features of the Study:
This report provides in-depth analysis of the global systemic scleroderma treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global systemic scleroderma treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GSK plc, Certa Therapeutics, Aisa Pharma, Inc., Corbus Pharmaceuticals, AbbVie, Inc., Biogen, Novartis AG, AstraZeneca, Celgen Corporation, ONO PHARMACEUTICAL CO., LTD., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH., and MediciNova, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global systemic scleroderma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global systemic scleroderma treatment market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2019 - 2032)
- Immunosuppressant
- Phosphodiesterase 5 inhibitors - PHA
- Endothelin Receptor Antagonists
- Calcium Channel Blockers
- Prostacyclin Analogues
- Others
- Type Insights (Revenue, USD Bn, 2019 - 2032)
- Limited Systemic Sclerosis
- Diffused Systemic Sclerosis
- Sine Sclerosis
- Route of Administration Insights (Revenue, USD Bn, 2019 - 2032)
- Oral
- Parenteral
- Others
- Distribution Channel Insights (Revenue, USD Bn, 2019 - 2032)
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Regional Insights (Revenue, USD Bn, 2019 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- GSK plc
- Certa Therapeutics
- Aisa Pharma, Inc.
- Corbus Pharmaceuticals
- AbbVie, Inc.
- Biogen
- Novartis AG
- AstraZeneca
- Celgen Corporation
- ONO PHARMACEUTICAL CO., LTD.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH.
- MediciNova, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Systemic Scleroderma Treatment Market, By Drug Class
- Systemic Scleroderma Treatment Market, By Type
- Systemic Scleroderma Treatment Market, By Route of Administration
- Systemic Scleroderma Treatment Market, By Distribution Channel
- Systemic Scleroderma Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
4. Systemic Scleroderma Treatment Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Immunosuppressant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Phosphodiesterase 5 inhibitors - PHA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Endothelin Receptor Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Prostacyclin Analogues
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Systemic Scleroderma Treatment Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Limited Systemic Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diffused Systemic Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Sine Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Systemic Scleroderma Treatment Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Systemic Scleroderma Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Systemic Scleroderma Treatment Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- GSK plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Certa Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aisa Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Corbus Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie, Inc.
- Biogen
- Novartis AG
- AstraZeneca
- Celgen Corporation
- ONO PHARMACEUTICAL CO., LTD.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH.
- MediciNova, Inc.
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
